Age-Related Macular Degeneration (AMD) Market Trends & Industry Overview

The Age-Related Macular Degeneration (AMD) Market is projected to reach US$ 20.88 billion by 2033, growing from US$ 11.42 billion in 2024 at a CAGR of 6.94% between 2025 and 2033. This strong growth is fueled by the expanding elderly population, lifestyle-related risk factors, better diagnostic tools, rising awareness, and continuous innovation in therapies.

Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=age-related-macular-degeneration-market-p.php

Renub Research’s report Age-Related Macular Degeneration (AMD) Global Market & Forecast provides detailed insights into the market by disease type (dry AMD, wet AMD), products (Eylea, Lucentis, Beovu, others), distribution channels (hospital pharmacy, specialty pharma, online pharmacy), and geographies (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa). It also covers company profiles, strategies, and financial insights for leading players.

Global AMD Market: An Overview

Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries among older adults. It affects the macula, the central part of the retina responsible for sharp vision. Over time, AMD causes a gradual decline in central vision, making it difficult to read, drive, recognize faces, or see fine details.

AMD is broadly classified into:

·        Dry AMD (Atrophic) – Characterized by drusen deposits, retinal pigment epithelium (RPE) atrophy, and gradual vision loss.

·        Wet AMD (Neovascular/Exudative) – Defined by abnormal blood vessel growth under the retina, leading to fluid leakage, swelling, and rapid central vision loss. Though less common (about 10% of cases), wet AMD causes nearly 90% of legal blindness.

Globally, the market is being driven by a strong pipeline of drugs, technological advancements, and a rapidly aging population. For instance, according to the Population Reference Bureau, the number of Americans aged 65+ is expected to grow from 58 million in 2022 to 82 million by 2050, creating significant demand for AMD treatments.

Market Growth Drivers

1. Innovative Treatment Options

The introduction of anti-VEGF (vascular endothelial growth factor) therapies has revolutionized AMD management, especially for wet AMD. These drugs, such as Eylea (Regeneron/Bayer) and Lucentis (Roche/Novartis), prevent abnormal blood vessel growth, helping stabilize or improve vision.

Future innovations include:

·        Gene therapies that target underlying genetic mutations.

·        Sustained-release drug delivery systems reducing the need for frequent injections.

·        Stem cell-based regenerative therapies for retinal repair.

Such breakthroughs promise improved patient outcomes and long-term disease management.

2. Growing Awareness and Early Screening

Healthcare organizations and advocacy groups are running awareness campaigns to educate the public about AMD symptoms and the importance of early detection. Rising screening rates are allowing earlier interventions, improving prognosis and slowing vision loss. In developing nations, healthcare access is improving, further supporting market expansion.

3. Rising Healthcare Investments

Governments and private investors are funding retinal disease research, supporting drug development and advanced diagnostic technologies. Increased clinical trials are paving the way for next-generation therapies targeting both wet and dry AMD, addressing previously unmet medical needs.

Key Market Challenges

1. High Treatment Costs

Anti-VEGF therapies require frequent injections, leading to high cumulative treatment costs. This creates financial strain for both patients and healthcare systems, particularly in low- and middle-income countries. Insurance coverage gaps exacerbate the issue, leaving many patients untreated.

Get Customization in the Report: https://www.renub.com/request-customization-page.php?gturl=age-related-macular-degeneration-market-p.php

2. Lack of Early Diagnosis

AMD often develops silently in its early stages. Many patients only seek medical help after significant vision loss, when treatment options are less effective. Limited routine screenings, especially in rural and underdeveloped regions, worsen delayed diagnosis and poor treatment outcomes.

Regional Market Insights

United States

The U.S. AMD market is expanding rapidly due to the aging population and advanced healthcare infrastructure. Anti-VEGF drugs dominate the market, and cutting-edge diagnostic technologies are widely available. However, treatment affordability remains a barrier, particularly for uninsured populations.

Germany

Germany is one of Europe’s leading AMD markets, with a strong healthcare system and access to innovative therapies. Anti-VEGF drugs are widely used, though high costs and limited dry AMD treatments remain challenges. Government reimbursement policies play a significant role in shaping market growth.

India

India’s AMD market is growing due to an aging population and increasing awareness of eye health. However, access to advanced diagnostics and therapies remains limited, especially in rural regions. High treatment costs are a major restraint, though government healthcare initiatives are expected to improve affordability in the coming years.

Saudi Arabia

The Saudi market is driven by rising cases of age-related eye diseases and government efforts to improve healthcare infrastructure. While urban centers provide access to advanced anti-VEGF therapies, rural areas still face challenges in affordability and availability.

Market Segmentation

By Disease Type

·        Dry AMD

·        Wet AMD

By Product

·        Eylea

·        Lucentis

·        Beovu

·        Others

By Distribution Channel

·        Hospital Pharmacies

·        Specialty Pharmacies

·        Online Pharmacies

By Country Coverage

·        North America: United States, Canada

·        Europe: Germany, France, Italy, Spain, United Kingdom, Belgium, Netherlands, Turkey

·        Asia Pacific: China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, New Zealand

·        Latin America: Brazil, Mexico, Argentina

·        Middle East & Africa: Saudi Arabia, UAE, South Africa

Key Market Players

Leading companies operating in the AMD market include:

·        Hoffmann-La Roche Ltd.

·        Bayer AG

·        Novartis AG

·        Regeneron Pharmaceuticals

·        AbbVie Inc.

·        GSK Plc

·        Bausch Health Companies Inc.

·        Alimera Sciences Inc.

These companies are investing heavily in R&D, strategic collaborations, and product launches to maintain competitive advantages.

Report Details

·        Base Year: 2024

·        Forecast Period: 2025–2033

·        Market Size: In US$ Billion

·        Segmentation: By Disease Type, Product, Distribution Channel, and Country

·        Coverage: 25+ Countries across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

·        Customization: Up to 20% free customization with additional countries, company profiles, or trade analysis upon request

About the Company

Renub Research is a global Market Research and Consulting Company with over 15 years of expertise in international Business-to-Business research, surveys, and consulting. We provide data-driven insights that help organizations make informed business decisions.

Our clientele spans across industries including Healthcare, Travel & Tourism, Food & Beverages, Power & Energy, IT & Telecom, Chemicals, Automotive, Retail, Agriculture, Logistics, and Construction. Our team comprises highly qualified professionals with advanced degrees in Finance, Marketing, Biotechnology, Medicine, IT, Environmental Science, and more.

Contact Us:

·        Company Name: Renub Research

·        Contact Person: Rajat Gupta

·        Phone (D): +91-120-421-9822 (IND)

·        Email: rajat@renub.com